We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Brain Imaging Explores the Myth of the Runner's High

By MedImaging staff writers
Posted on 25 Mar 2008
Medical specialists and most runners agree that prolonged jogging raises people's spirits. More...
Moreover, many believe that the body's own opioids, so-called endorphins, are the cause of this. However, this has never been proved until now. Utilizing imaging technology, researchers have succeeded in demonstrating the existence of an "endorphin-driven runner's high.”

In an imaging study, researchers from the Technische Universität München (TUM; Germany) and the University of Bonn (Germany) were able to show, for the first time, increased release of endorphins in specific areas of the athletes' brains during a two-hour jogging session. Their results are also relevant for patients suffering from chronic pain, because the body's own opiates are generated in areas of the brain, which are involved in the suppression of pain. The researchers showed that jogging not only makes one "high,” but can also relieve pain. The results of the study were published in the online Advance Access issue published on February 21, 2008, in the journal Cerebral Cortex.

Endurance sports have long been seen as reducing stress, relieving anxiety, enhancing moods, and decreasing the perception of pain. The high that accompanies jogging even led to the creation of its own term, runner's high. Yet, the cause of these positive effects on the senses was not clear until now. The most popular theory was and still is the "endorphin hypothesis,” which claimed that there was increased production of the body's own opioids in the brain. However, until now, direct proof of this theory could not be substantiated; for technical reasons, it was a constant source of controversial discussions in scientific circles. The result was that the myth of "runner's high through endorphins” lived on.

Scientists from the fields of nuclear medicine, neurology, and anesthesia at the Technische Universität München and the University of Bonn have now subjected the endorphin theory to closer evaluation. Ten athletes were scanned before and after a two-hour long-distance run using positron emission tomography (PET) imaging. For this they used the radioactive substance [18F]diprenorphine ([18F]FDPN), which binds to the opiate receptors in the brain and hence competes with endorphins.

"The more endorphins are produced in the athlete's brain, the more opiate receptors are blocked," stated Prof. Henning Boecker, who coordinated the research at TUM and who is now in charge of the Functional Neuroimaging Group at the department of radiology, University Hospital Bonn. "Respectively, the opioid receptor binding of the [18F]FDPN decreases, since there is a direct competition between endorphins in the brain and the injected ligand.”

By comparing the images before and after two hours of long distance running the researchers could demonstrate a significantly decreased binding of the [18F]FDPN-ligand. This is a strong argument in favor of an increased production of the body's own opioids while doing long-distance running.

"We could validate for the first time an endorphin driven runner's high and identify the affected brain areas,” stated Prof. Boecker. "It's interesting to see that the affected brain areas were preferentially located in prefrontal and limbic brain regions which are known to play a key role in emotional processing. Moreover, we observed a significant increase of the euphoria and happiness ratings compared to the ratings before the running exercise.”

Prof. Thomas Tölle, who for several years has been head of a research group called Functional Imaging of Pain at TUM, added, "Our evaluations show that the more intensively the high is experienced, the lower the binding of [18F]FDPN was in the PET scan. And this means that the ratings of euphoria and happiness correlated directly with the release of the endorphins. The fact that the endorphins are also released in areas of the brain that are at the center of the suppression of pain was not quite unexpected, but even this proof was missing. Now we hope that these images will also impress our pain patients and will motivate them to take up sports training within their available limits.”


Related Links:
Technische Universität München
University of Bonn

Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
X-Ray System
Leonardo DR mini III
Imaging Table
Stille imagiQ2
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.